Your browser doesn't support javascript.
loading
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss.
He, Shuning; Zimmerman, Mark W; Layden, Hillary M; Berezovskaya, Alla; Etchin, Julia; Martel, Megan W; Thurston, Grace; Jing, Chang-Bin; van Rooijen, Ellen; Kaufman, Charles K; Rodig, Scott J; Zon, Leonard I; Patton, E Elizabeth; Mansour, Marc R; Look, A Thomas.
Affiliation
  • He S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. shuning_he@dfci.harvard.edu.
  • Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Layden HM; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Berezovskaya A; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Etchin J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Martel MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Thurston G; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Jing CB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • van Rooijen E; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA, USA.
  • Kaufman CK; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA, USA.
  • Rodig SJ; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
  • Zon LI; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA, USA.
  • Patton EE; MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Mansour MR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. m.mansour@ucl.ac.uk.
  • Look AT; Department of Hematology, UCL Cancer Institute, University College London, London, UK. m.mansour@ucl.ac.uk.
Oncogene ; 40(38): 5718-5729, 2021 09.
Article in En | MEDLINE | ID: mdl-34331013
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thiophenes / Bridged Bicyclo Compounds, Heterocyclic / Neurofibromin 1 / PTEN Phosphohydrolase / MTOR Inhibitors / Melanoma Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Thiophenes / Bridged Bicyclo Compounds, Heterocyclic / Neurofibromin 1 / PTEN Phosphohydrolase / MTOR Inhibitors / Melanoma Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido